Serum soluble factors induce the proliferation, alkaline phosphatase activity and transforming growth factor-β signal in osteoblastic cells in the patient with hepatitis C-associated osteosclerosis

Experimental and Clinical Endocrinology and Diabetes

Volumn 114, Issue 10, 2006, Pages 599-604

  Kaji, Hiroshi ^a   Naito, J ^a   Sowa, H ^a   Sugimoto, T ^b   Chihara, K ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

Author keywords

Osteoblast; Osteosclerosis TGF ; smad3

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ALKALINE PHOSPHATASE; CELL NUCLEUS ANTIGEN; PARATHYROID HORMONE; SMAD PROTEIN; SMAD PROTEIN 3; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ADULT; ANIMAL CELL; ANTIGEN EXPRESSION; ARTICLE; BONE BIOPSY; BONE MASS; BONE PAIN; BONE RADIOGRAPHY; CASE REPORT; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVITY; HEPATITIS C; HUMAN; LABORATORY TEST; MALE; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOSCLEROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

3T3 CELLS; ALKALINE PHOSPHATASE; ANIMALS; BONE AND BONES; BONE DEVELOPMENT; CELL DIVISION; DENSITOMETRY, X-RAY; DIPHOSPHONATES; GENE EXPRESSION REGULATION; HEPATITIS C; HUMANS; MALE; MICE; MIDDLE AGED; MITOCHONDRIA; OSTEOBLASTS; OSTEOSCLEROSIS; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 33846219494     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-924399     Document Type: Article

References (30)

1. Beck LS, Amento EP, Xu Y, Deguzman L, Lee WP, Nguyen T, Gillett NA. TGF-β1 induces bone closure of skull defects: Temporal dynamics of bone formation in defects exposed to rhTGF-β1. J Bone Miner Res 1993; 8: 753-761
2. Beyer SH, Parfitt AM, Shih MS, Anderson Q, Heath III H. Idiopathic acquired diffuse osteosclerosis in a young woman. J Bone Miner Res 1990;5:1257-1263
3. Borton AJ, Frederick JP, Datto MB, Wang XF, Weinstein RS. The loss of Smad3 results in a lower rate of bone formation and osteopenia through dysregulation of osteoblast differentiation and apoptosis. J Bone Miner Res 2001; 16: 1754-1764
4. Diamond T, Depczynski B. Acquired osteosclerosis associated with in travenous drug use and hepatitis C infection. Bone 1996; 19: 679-683
5. Hassoun A, Nippoldt TB, Tiegs RD, Khosla S. Hepatitis C-associated osteosclerosis: an unusual syndrome of acquired osteosclerosis in adults. Am J Med 1997; 103: 70-73
6. Janssens K, Gershoni-Baruch R, Guanabens N, Migone N, Ralston S, Bonduelle M, Lissens W, Van Maldergem L, Vanhoenacker F, Verbruggen L, Van Hul W. Mutations in the gene encoding the latency-associated peptide of TGF-β1 cause Camurati-Engelmann disease. Nat Genet 2000; 26: 273-275
7. Janssens K, ten Dijke P, Ralston SH, Bergmann C, Van Hul W. Transforming growth factor-β1 mutations in Camurati-Engelmann disease lead to increased signaling by altering either activation or secretion of the mutant protein. J Biol Chem 2003; 278: 7718-7724
8. Janssens K, Ten Dijke P, Janssens S, Van Hul W. TGF-β1 to the bone. Endcr Rev 2005; 26: 743-774
9. Janssens K, Vanhoenacker F, Bonduelle M, Verbruggen L, Van Maldergem L, Ralston S, Guanabens N, Migone N, Wientroub S, Divizia MT, Bergmann C, Bennett C, Simsek S, Melancon S, Cundy T, Van Hul W. Camurati-Engelmann disease: review of the clinical, radiological and molecular data of 24 families and implications towards diagnostics and treatment. J Med Genet 2006; 43: 1-11
10. Jeach RJ, Singer FR, Roodman GD. Genetics of Paget's disease of the bone. J Clin Endocrinol Metab 2001; 86: 24-28
11. Jennings JC, Mohan S. Heterogeneity of latent transforming growth factor- isolated from bone matrix proteins. Endocrinology 1990; 126: 1014-1021
12. Joyce ME, Roberts AB, Sporn MB, Bolander ME. Transforming growth factor-β and the initiation of chondrogenesis and osteogenesis in the rat femur. J Cell Biol 1990; 110: 2195-2207
13. Kaji H, Canaff L, Lebrun JJ, Goltzman D, Hendy GN. Inactivation of menin, a Smad3-interacting protein, blocks TGF-β signaling. Proc Natl Acad Sci USA 2001; 98: 3837-3842
14. Kinoshita A, Saito T, Tomita H, Makita Y, Yoshida K, Ghadami M, Yamada K, Kondo S, Ikegawa S, Mishimura G, Fukushima Y, Nakagomi T, Saito H, Sugimoto T, Kamegaya M, Hisa K, Murray JC, Taniguchi N, Niikawa N, Yoshiura K. Domain-specific mutations in TGF β 1 result in Camurati-Engelmann disease. Nat Genet 2000; 26: 19-20
15. Khosla S, Hassoun AA, Baker BK, Liu F, Zein NN, Whyte MP, Reasner CA, Nippoldt TB, Tiegs RD, Hintz RL, Conover CA. Insulin-like growth factor system abnormalities in hepatitis C-associated osteosclerosis. Potential insights into increasing bone mass in adults. J Clin Invest 1998; 101: 2165-2173
16. Manganelli P, Giuliani N, Fietta P, Mancini C, Lazzaretti M, Pollini A, Quaini F, Pedrazzoni M. OPG/RANKL system imbalance in a case of hepatitis C-associated osteosclerosis: the pathogenetic key? Clin Rheumatol 2005; 24: 296-300
17. Massague J, Chen YG. Controlling TGF-β signaling. Genes Dev 2000; 14: 627-644
18. Massague J, Wotton D. Transcriptional control by the TGF-β/Smad signaling system. EMBO J 2000; 19: 1745-1754
19. Noda M, Camilliere JJ. In vivo stimulation of bone formation by transforming growth factor-β. Endocrinology 1989; 124: 2991-2994
20. Rodan GA. Bone homeostasis. Proc Natl Acad Sci USA 1998; 95: 13361-13362
21. Roodman GD, Windle JJ. Paget disease of bone. J Clin Invest 2005; 115: 200-208
22. Rosen D, Miller SC, DeLeon E, Thompson AY, Bentz H, Mathews M, Adams S. Systemic administration of recombinant transforming growth factor 2 (rTGF-β2) stimulates parameters of cancellous bone formation in juvenile and adult rats. Bone 1994; 15: 355-359
23. Shaker JL, Reinus WR, Whyte MP. Hepatitis C-associated osteosclerosis: late onset after blood transfusion in an elderly woman. J Clin Endocrinol Metab 1998; 83: 93-98
24. Sowa H, Kaji H, Yamaguchi T, Sugimolo T, Chihara K. Smad3 promotes alkaline phosphatase activity and mineralization of osteoblastic MC3T3-E1 cells. J Bone Miner Res 2002a: 17: 1190-1199
25. Sowa H, Kaji H, Yamaguchi T, Sugimoto T, Chihara K. Activations of ERK1/2 and JNK by transforming growth factor β negatively regulate Smad3-induced alkaline phosphatase activity and mineralizatiion in mouse osteoblastic cells. J Biol Chem 20025; 277: 36024-36031
26. Sowa H, Kaji H, Iu MF, Tsukamoto T, Sugimoto T, Chihara K. Parathyroid hormone-Smad3 axis exerts anti-apoptotic action and augments anabolic action of transforming growth factor β in osteoblasts. J Biol Chem 2003; 278: 52240-52252
27. Sparkes RS, Graham CB. Camurati-Engelmann disease: genetics and clinical manifestations with a review of the literature. J Med Genet 1972; 9: 73-85
28. Villareal DT, Murphy WA, Teitelbaum SL, Arens MQ, Whyte MP. Painful diffuse osteosclerosis after intravenous drug abuse. Am J Med 1992; 93: 371-381
29. Whyte MP, Teitelbaum SL, Reinus WR. Doubling skeletal mass during adult life: the syndrome of diffuse osteosclerosis after intravenous drug abuse. J Bone Miner Res 1996; 11: 554-558
30. Whyte MP, Reasner CA. Hepatitis C-associated osteosclerosis after blood transfusion. Am J Med 1997; 102: 219-220